Venclexta: payments to doctors
Payments that named Venclexta as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $12.8M
- Providers
- 13,824
- Transactions
- 73,955
- Average per transaction
- $174
The per-transaction average — $174 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 13,824 providers the average total is $929, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AbbVie | $9,998,422 | 77.8% |
| Genentech USA, Inc. | $2,049,316 | 16.0% |
| Genentech, Inc. | $569,176 | 4.4% |
| F. Hoffmann-la Roche AG | $222,737 | 1.7% |
| Hoffmann-la Roche Limited | $3,418 | 0.0% |
| Pharmacyclics LLC, An Abbvie Company | $599 | 0.0% |
| Roche Products Limited | $12 | 0.0% |